Anzeige
Erschienen in:
01.06.2012 | Diagnostic Neuroradiology
Imaging parameters of high grade gliomas in relation to the MGMT promoter methylation status: the CT, diffusion tensor imaging, and perfusion MR imaging
Erschienen in: Neuroradiology | Ausgabe 6/2012
Einloggen, um Zugang zu erhaltenAbstract
Introduction
We hypothesized that methyl-guanine methyl transferase (MGMT) promoter methylation status, a predictor of the chemosensitivity for high grade gliomas (HGGs), may be associated with computed tomography (CT)/magnetic resonance (MR) imaging variables.
Methods
Out of 38 consecutive patients with HGGs, 24 patients whose MGMT promoter methylation status was available [12 men and 12 women; median age, 49 years; age range, 22–79 years; WHO grade III (n = 7), WHO grade IV (n = 17)] were enrolled retrospectively. CT attenuation, apparent diffusion coefficient (ADC), fractional anisotropy (FA), and relative cerebral blood volume (rCBV) were measured for enhancing tumors. Qualitative imaging features were also analyzed. Mann–Whitney and Fisher’s exact tests were used to evaluate relationships between MGMT promoter methylation status and imaging variables.
Results
Maximum CT attenuation was significantly lower in the methylated MGMT promoter group than that in the unmethylated MGMT promoter group (30.3 ± 9.5 HU versus 39.2 ± 4.7 HU, respectively, p = 0.009). While ADC values tended to be higher in the methylated group than in the unmethylated group (p = 0.055), ADC ratio was significantly higher, and the FA and FA ratios were significantly lower in the methylated group than in the unmethylated group (p = 0.032, p = 0.006 and p = 0.007, respectively). In contrast, rCBV ratio did not differ between the two groups (p = 0.380).
Regarding imaging features, only ill-defined margin was seen more frequently in the methylated group than in the unmethylated group (45.5% versus 7.7%, respectively, p = 0.048).
Conclusion
Preoperative imaging can predict MGMT promoter methylation status, which is of paramount importance for predicting treatment response to chemotherapy with an alkylating agent.